Title
De Novo Damaging Variants, Clinical Phenotypes, and Post-Operative Outcomes in Congenital Heart Disease.

Permalink
https://escholarship.org/uc/item/7mk6v3w8

Journal
Circulation. Genomic and precision medicine, 13(4)

ISSN
2574-8300

Authors
Boskovski, Marko T
Homsy, Jason
Nathan, Meena
et al.

Publication Date
2020-08-01

DOI
10.1161/circgen.119.002836

Peer reviewed
De Novo Damaging Variants, Clinical Phenotypes, and Post-Operative Outcomes in Congenital Heart Disease

Marko T. Boskovski, MD, MHS, MPH; Jason Homsy, MD, PhD; Meena Nathan, MD, MPH; Lynn A. Sleeper, ScD; Sarah Morton, MD, PhD; Kathryn B. Manheimer, PhD; Angela Tai, BA; Joshua Gorham, BA; Matthew Lewis, MD; Michael Swartz, PhD; George M. Alfieris, MD; Emile A. Bacha, MD; Mohsen Karimi, MD; David Meyer, MD; Khanh Nguyen, MD; Daniel Bernstein, MD; Angela Romano-Adesman, MD; George A. Porter Jr., MD, PhD; Elizabeth Goldmuntz, MD; Wendy K. Chung, MD, PhD; Deepak Srivastava, MD; Jonathan R. Kaltman, MD; Martin Tristani-Firouzi, MD; Richard Lifton, MD; Amy E. Roberts, MD; J. William Gaynor, MD; Bruce D. Gelb, MD; Richard Kim, MD; Jonathan G. Seidman, MD, PhD; Martina Brueckner, MD; John E. Mayer Jr., MD; Jane W. Newburger, MD, MPH*; Christine E. Seidman, MD*

BACKGROUND: De novo genic and copy number variants are enriched in patients with congenital heart disease, particularly those with extra-cardiac anomalies. The impact of de novo damaging variants on outcomes following cardiac repair is unknown.

METHODS: We studied 2517 patients with congenital heart disease who had undergone whole-exome sequencing as part of the CHD GENES study (Congenital Heart Disease Genetic Network).

RESULTS: Two hundred ninety-four patients (11.7%) had clinically significant de novo variants. Patients with de novo damaging variants were 2.4 times more likely to have extra-cardiac anomalies (P=5.63×10−12). In 1268 patients (50.4%) who had surgical data available and underwent open-heart surgery exclusive of heart transplantation as their first operation, we analyzed transplant-free survival following the first operation. Median follow-up was 2.65 years. De novo variants were associated with worse transplant-free survival (hazard ratio, 3.51; P=5.33×10−04) and longer times to final extubation (hazard ratio, 0.74; P=0.005). As de novo variants had a significant interaction with extra-cardiac anomalies for transplant-free survival (P=0.003), de novo variants conveyed no additional risk for transplant-free survival for patients with these anomalies (adjusted hazard ratio, 1.96; P=0.06). By contrast, de novo variants in patients without extra-cardiac anomalies were associated with worse transplant-free survival during follow-up (hazard ratio, 11.21; P=1.61×10−05) than that of patients with no de novo variants. Using agnostic machine-learning algorithms, we identified de novo copy number variants at 15q25.2 and 15q11.2 as being associated with worse transplant-free survival and 15q25.2, 22q11.21, and 3p25.2 as being associated with prolonged time to final extubation.

CONCLUSIONS: In patients with congenital heart disease undergoing open-heart surgery, de novo variants were associated with worse transplant-free survival and longer times on the ventilator. De novo variants were most strongly associated with adverse outcomes among patients without extra-cardiac anomalies, suggesting a benefit for preoperative genetic testing even when genetic abnormalities are not suspected during routine clinical practice.

REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01196182.

Key Words: genomics ◼ congenital heart disease ◼ heart transplantation ◼ mortality ◼ survival
Congenital heart disease (CHD) is the most common birth defect, occurring in nearly 1% of live births.\textsuperscript{1-3} Despite advances in diagnosis, cardiac surgery, and perioperative management, CHD remains a leading cause of infant and child mortality. Recent discoveries have identified de novo damaging variants in \(\approx 10\%\) of patients with diverse CHD malformations.\textsuperscript{4-19} These variants include de novo single nucleotide variants and small insertions or deletions that are predicted to adversely impact the function or expression of one protein (denoted damaging genic variants [DGVs]), as well as de novo copy number variants (CNVs) that delete or duplicate contiguous genes. Damaging de novo variants in genes that are expressed in the developing heart and other organs are significantly more prevalent in CHD patients with extra-cardiac anomalies (ECAs), compared with patients with isolated CHD.\textsuperscript{4,5,18,19} Given the potential pleiotropic effects of de novo variants, an emerging question is whether genotype also influences broader clinical outcomes in patients with CHD.

A few prior studies have investigated large CNVs (>300 kb) discovered using genotype arrays in small cohorts. These studies demonstrated worse linear growth in CHD patients with single ventricle\textsuperscript{20}; >3-fold increase in risk of death or transplant among nonsyndromic CHD patients\textsuperscript{21} and longer surgical bypass times, more re-operations, and increased intensive care stays in patients with chromosome 22q11.2 deletions and tetralogy of Fallot, truncus arteriosus, or interrupted aortic arch.\textsuperscript{22,23} To date, no studies have comprehensively examined the impact of de novo variants on postoperative outcomes in CHD patients with and without ECAs.

To better elucidate the influence of de novo genotype on clinical characteristics and postoperative outcomes after open-heart surgery, we analyzed 2517 CHD trios (patients and biological parents) enrolled by the Pediatric Cardiac Genomics Consortium. Using exome sequences, we identified clinically significant de novo variants, both CNVs and DGVs\textsuperscript{18} and analyzed their associations with ECAs. Among patients undergoing open-heart surgery, we then investigated the association of de novo variants with transplant-free survival and postoperative respiratory support, and their interaction with ECAs.

### RESULTS

#### De Novo Variants Are Associated With ECA

Of 2517 patients with CHD in our cohort, 294 (11.7%) carried de novo variants: 131 (5.2%) had CNVs (3.2-fold more frequent than controls) and 169 (6.7%) had DGVs in multi-hit genes (denoted throughout as clinically significant; Methods and Tables IV through VIII in the Data Supplement). Patients with de novo variants were 2.4 times more likely to have ECAs \((P=5.63\times 10^{-12})\). This association persisted when considering only patients with de novo CNVs, novel de novo CNVs not commonly associated with CHD (Table IX in the Data Supplement), de novo DGVs, and de novo DGVs in genes highly expressed in the heart (Table 1 and Methods in the Data Supplement).

#### De Novo Variants Are Associated With Worse Transplant-Free Survival and Time to Extubation After Open-Heart Surgery

Surgical data were available in 1413 patients with CHD (Figure 1A) and all who had open-heart surgery exclusive of those with heart transplantation as their first surgery \((n=1268\) patients) were studied for postoperative transplant-free survival. Among these patients, 947 patients also had ventilator data for analyses of respiratory outcomes. Surgical patients, compared with those in whom surgical data were not available, were younger, had more severe CHD, and had more ECAs (Figure 1B).

Among the 1268 open-heart surgery patients, 143 (11.3%) had de novo CNVs and clinically significant DGVs (Figure 1B). ECAs occurred more frequently among surgical CHD patients with de novo variants. There was a difference in STAT (Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery) mortality categories (reflecting increasing risk and severity of surgery) between those with and without de novo variants, primarily due to differences in categories 4 and 5. The remaining demographic and operative factors, as well as follow-up times and cardiac diagnoses, were similar (Table 2 and Table X in the Data Supplement).
De novo variants were associated with significantly worse transplant-free survival during a median follow-up of 2.65 years after the first open-heart surgery in unadjusted and adjusted analyses taking into account age, total cardiopulmonary support time, STAT mortality category, center where the surgery was performed and preoperative factors (adjusted hazard ratio [HR], 3.51 [95% CI, 1.96–6.07]; Methods and Table XI in the Data Supplement). This association was robust in sensitivity analyses that excluded individual STAT categories (Table XII in the Data Supplement). Subgroup analyses showed worse transplant-free survival in patients carrying de novo CNVs, novel de novo CNVs and de novo DGVs (Table 3, Figure 2, and Figure I in the Data Supplement). Atrial and ventricular septal defects were the most common malformations encountered, and de novo variants were also associated with worse transplant-free survival in patients with left-sided lesions (adjusted HR, 3.40, P=0.003; Table XIII in the Data Supplement).

Subgroup analyses showed longer time to final extubation in patients with de novo CNVs, novel de novo CNVs, but not de novo DGVs (Table 3, Figure 2, and Figure I in the Data Supplement).

### De Novo Variants, ECA, and Clinical Outcomes

Since de novo variants are associated with ECAs, and ECAs have been reported to lead to worse outcomes, we investigated the association between the 2 and clinical outcomes. De novo variants and ECAs had a significant interaction (P=0.003) in their association with transplant-free survival; that is, the magnitude of association between de novo variants and death or transplant varied according to the presence or absence of ECAs. In patients with ECAs, there was no additional hazard associated with the presence of de novo variants on transplant-free survival (HR, 1.96 [95% CI, 0.96–3.79], P=0.06). In contrast, among patients without ECAs, de novo variants were associated with worse transplant-free survival (HR, 11.21 [95% CI, 4.12–29.13], P=1.61×10−05; Figure 3). Moreover, transplant-free survival of patients with versus without variants in nonsyndromic genes (adjusted HR, 3.84 [95% CI, 2.12–6.94]; P=8.77×10−06) was worse than similar comparisons of variants in syndromic genes (adjusted HR, 1.21 [95% CI, 0.28–5.31]; P=0.80).

Both de novo variants (HR, 0.75 [95% CI, 0.61–0.94], P=0.01) and ECAs (HR, 0.86 [95% CI, 0.76–0.99], P=0.03) were independently associated with longer time to final extubation. However, there was no significant interaction between de novo variants and ECAs with regard to time to final extubation (P=0.89).

| Table 1. Frequency of ECA in Patients With De Novo Damaging Variants |
|---------------------------------------------------------------|
| No. of Patients With ECAs (%) | Odds Ratio (95% CI) | P Value |
| De novo variant (copy number or damaging genic variant)        |
| Present (294 patients) | 176 (59.9) | 2.4 (1.8–3.1) | 5.63×10−12 |
| Absent (2223 patients) | 856 (38.5) | | |
| De novo copy number variant                                    |
| Present (131 patients) | 78 (59.5) | 2.2 (1.5–3.2) | 1.02×10−05 |
| Absent (2386 patients) | 954 (40.0) | | |
| Novel de novo copy number variant                              |
| Present (85 patients) | 50 (58.8) | 2.1 (1.4–3.4) | 6.77×10−04 |
| Absent (2386 patients) | 954 (40.0) | | |
| De novo damaging genic variant*                                 |
| Present (169 patients) | 102 (60.4) | 2.3 (1.7–3.2) | 1.69×10−07 |
| Absent (2348 patients) | 930 (39.6) | | |
| De novo damaging genic variant* with high heart expression     |
| Present (129 patients) | 83 (64.3) | 2.7 (1.9–4.1) | 5.83×10−04 |
| Absent (2388 patients) | 949 (39.7) | | |

ECA indicates extra-cardiac anomalies.
*Includes only de novo clinically significant (occur in multi-hit genes; Methods in the Data Supplement).
Machine-Learning Insights Into High-Risk De Novo Variants Associated With Adverse Clinical Outcomes

We used agnostic, model-free, machine-learning methods to determine if some de novo variants were associated with worse clinical outcomes (detailed in Methods in the Data Supplement). Analyses were limited to the 1268 CHD patients with surgical data, who were randomly assigned into discovery and validation cohorts. For each of one thousand pervariants, we sought to identify de novo variants that were associated with worse transplant-free survival and prolonged time to final extubation (Figure 4). For transplant-free survival de novo CNVs at 2 loci, 15q25.2 and 15q11.2, were identified in both the discovery and validation cohorts at substantial frequencies (48% and 43%, respectively; Figure 4A). Patients with CHD harboring these high-risk CNVs had significantly worse transplant-free survival compared with the remaining de novo variants (HR, 17.44; \( P = 3.53 \times 10^{-04} \)) and those with other de novo variants (HR, 2.68 [95% CI, 1.47–4.63], \( P = 0.002 \)).

De novo CNVs affecting chromosomes 15q25.2, 22q11.21 and 3p25.1-26.3 were most frequently identified in both the discovery and validation cohorts (50%, 34%, and 29% of pervariants, respectively) in association with prolonged times to final extubation compared with the remaining de novo variants (HR, 0.38 [95% CI, 0.17–0.86]), although the remaining de novo variants also had a residual hazard for prolonged intubation (HR, 0.80 [95% CI, 0.65–0.98]).

DISCUSSION

Genomic analyses of 2517 patients with CHD and their parents revealed clinically significant de novo variants in 11.7% of patients. Patients with de novo variants were more likely to have ECAs, reinforcing prior evidence that de novo variants are more prevalent in syndromic than in isolated CHD. In a subset of 1268 patients with CHD who had undergone open-heart surgery and for whom we had surgical data, we also found that de novo variants were associated with worse transplant-free survival, as well as worse postoperative respiratory outcomes, including a greater likelihood of postoperative reintubation, and longer times to first and final extubation. Importantly, de novo variants were strongly associated...
with adverse outcomes among patients without ECAs, in whom genetic abnormalities might not have been suspected during routine clinical practice.

Smaller studies have previously reported associations between CNVs and clinical outcomes, but this is the first large scale study to examine the overall impact of

Table 2. Characteristics of Patients With and Without De Novo Damaging Variants

| Characteristic                          | CHD Patients With De Novo Variant | CHD Patients Without De Novo Variant | P Value |
|----------------------------------------|----------------------------------|-------------------------------------|---------|
| Patient, n (%)                         | 143 (11.3)                       | 1125 (88.7)                         |         |
| Age at surgery, y                      | 0.41 (0.02–3.52)                 | 0.38 (0.02–3.31)                    | 0.44    |
| Age group at surgery                   |                                 |                                     |         |
| Neonate                                | 389 (34.6)                       | 55 (38.5)                           |         |
| Infant                                 | 326 (29)                         | 38 (26.6)                           |         |
| Child                                  | 362 (32.2)                       | 42 (29.4)                           |         |
| Adult                                  | 48 (4.3)                         | 8 (5.6)                             |         |
| Male sex, n (%)                        | 83 (58)                          | 659 (58.6)                          | 0.93    |
| Weight, kg                             | 5.52 (3.4–11.22)                 | 5.8 (3.4–14)                        | 0.54    |
| Height, cm                             | 61 (50.5–98)                     | 62.15 (51–98)                       | 0.36    |
| Race or ethnic group, n (%)            |                                 |                                     |         |
| White                                  | 117 (81.8)                       | 937 (83.3)                          |         |
| More than one race                     | 11 (7.7)                         | 75 (6.7)                            |         |
| Black                                  | 8 (5.6)                          | 67 (6)                              |         |
| Asian                                  | 6 (4.2)                          | 32 (2.8)                            |         |
| Unknown                                | 1 (0.7)                          | 12 (1.1)                            |         |
| Pacific Islander                       | 0 (0)                            | 1 (0.1)                             |         |
| Native American                        | 0 (0)                            | 1 (0.1)                             | 0.96    |
| Premature, n (%)                       | 25 (17.5)                        | 147 (13.1)                          | 0.16    |
| Extra-cardiac anomaly, n (%)           | 92 (64.3)                        | 484 (43)                            | 1.83×10⁻⁶⁶ |
| Neurodevelopmental delay, n (%)        | 41 (28.7)                        | 150 (13.3)                          | 3.64×10⁻⁰⁷ |
| Preoperative factors, n (%)            |                                 |                                     |         |
| Cardiopulmonary resuscitation          | 6 (0.5)                          | 0 (0.0)                             | 1.00    |
| Shock, persistent at time of operation | 10 (0.9)                         | 0 (0.0)                             | 0.61    |
| Mechanical circulatory support         | 3 (0.3)                          | 0 (0.0)                             | 1.00    |
| Mechanical ventilation to treat cardiorespiratory failure | 100 (8.9) | 14 (9.8) | 0.76 |
| Neurological deficit                   | 18 (1.8)                         | 5 (3.5)                             | 0.17    |
| Renal dysfunction or renal failure requiring dialysis | 7 (0.6) | 1 (0.7) | 1.00 |
| Any other preoperative factor          | 231 (20.5)                       | 33 (23.1)                           | 0.51    |
| STAT mortality category, n (%)         |                                 |                                     |         |
| 1                                      | 43 (30.1)                        | 361 (32.1)                          |         |
| 2                                      | 31 (21.7)                        | 233 (20.7)                          |         |
| 3                                      | 25 (17.5)                        | 205 (18.2)                          |         |
| 4                                      | 14 (9.8)                         | 186 (16.5)                          |         |
| 5                                      | 30 (21)                          | 140 (12.4)                          | 0.03    |
| Total cardiopulmonary support time, h  | 1.42 (0.9–1.98)                  | 1.45 (0.93–2.07)                    | 0.69    |
| Aortic cross-clamp time, h             | 0.83 (0.58–1.29)                 | 0.85 (0.53–1.27)                    | 0.59    |
| Follow-up time                         | 2.45 (0.15–4.71)                 | 2.65 (0.31–4.56)                    | 0.91    |
| Total no. of surgeries during follow-up| 1 (1–2)                          | 1 (1–2)                             | 0.26    |
| 30-day mortality                       | 9 (0.8)                          | 4 (2.8)                             | 0.05    |
| Death                                  | 12 (8.4)                         | 34 (3)                              | 0.003   |
| Heart transplant                       | 7 (4.9)                          | 14 (1.2)                            | 0.01    |
| Death or heart transplant              | 18 (12.6)                        | 46 (4.1)                            | 1.14×10⁻²⁴ |

CHD indicates congenital heart disease; and STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery.
all de novo variants, including DGVs, on postoperative outcomes. Our findings are consistent with prior studies that have demonstrated worse transplant-free survival in patients with large CNVs, as well as in patients with 22q11.2 deletions. Notably, subgroup analyses that excluded CNVs commonly associated with CHD, including 22q11.2 deletions, still demonstrated significantly worse outcomes, suggesting that the observed associations are not solely driven by patients with well-established CNVs. Rare, not commonly reported de novo CNVs were equally important determinants of postoperative outcomes.

DGVs that occurred 2 or more times within the same gene had significant associations with ECAs, transplant-free survival, and respiratory outcomes. This observation supports 2 conclusions. First, some DGVs, particularly those identified only once in the study cohort, were likely incidental mutations that did not account for CHD and associated phenotypes. As larger cohorts are studied, we expect that a more complete repertoire of genes that are critical for heart and organ development will emerge. Second, because DGVs affect a single gene, while the majority of CNVs in this cohort spanned multiple genes, the observed associations likely reflect the pleiotropic effects of individual genes. Further elucidation of the developmental function of variants in these genes may inform mechanisms for these clinically important associations.

Several prior studies demonstrated a significant enrichment of de novo variants among CHD patients with ECAs. These findings indicate that some de novo variants cause pleiotropic effects that are responsible for both cardiac and extra-cardiac defects. Moreover, because de novo variants are associated with ECAs, and ECAs are associated with worse outcomes, ECAs are in the causal pathway between de novo mutations and worse surgical outcomes. Consistent with this interpretation, our interaction analyses demonstrated that the magnitude of the association between de novo variants and death/transplant was different for patients with versus those without ECAs. Within the subgroup of patients with ECAs, the association of de novo variants with adverse outcome was modest and did not reach statistical significance.

CHD patients without ECAs have a lower burden of de novo variants. But among those without ECAs who do have de novo variants, our study provided the first and strong evidence that these genotypes were associated with a statistically significantly greater hazard of mortality or cardiac transplantation during a median follow-up of 2.65 years. This finding may reflect the impact of de novo variants on cardiopulmonary demands, resilience after open-heart surgery, or other effects independent of overt ECAs. The effects of unrecognized de novo variants might contribute to increased, early mortality of patients with simple (isolated, uncomplicated septal defects and patent ductus arteriosus) CHD. The mechanisms and genetic pathways through which de novo variants and ECAs act warrant further study.

Currently, the majority of patients with CHD and ECAs undergo genetic testing, which leads to early diagnosis, further diagnostic testing as dictated by the specific genetic diagnosis, and anticipatory guidance over time. Our data suggest that genetic testing is also important in CHD patients without clinically overt ECAs for 2 reasons. First, these patients also have significantly worse outcomes.2,22,23
outcomes, and second, although we excluded from sequencing patients with clinically diagnosed syndromic CHD, a number of syndromic variants were nevertheless discovered by exome sequence analyses. This suggests that even at high-volume centers, many syndromic patients remain under-diagnosed.

To explore the relationships between specific genotypes and open-heart surgery outcomes in patients with CHD, we leveraged model-free machine-learning predictive tools. Among all CHD subjects with relevant post-operative data, we found that specific de novo variants were associated with the highest risks of mortality, heart

---

**Figure 2.** Kaplan-Meier curves depicting (A) time to death or heart transplantation following first open-heart surgery and (B) time to final extubation following open-heart surgery for congenital heart disease patients with and without de novo damaging variants (includes only clinically significant damaging genic variants [DGVs]). Adjusted hazard ratios (HR) are shown.
transplantation, or prolonged time to extubation. Because we had only one CHD cohort with both genetic and clinical data, we used permutation analyses to confirm these associations. Our finding that de novo CNVs on chromosome 22q11.2 conveyed high risk for prolonged time to extubation provides support for this approach, as independent data associate this locus with respiratory dysfunction.23,28 Overall, we identified de novo CNVs at 2 loci (15q25.2 and 15q11.2) associated with markedly worse transplant-free survival and 3 loci (15q25.2, 22q11.2, and 3p25.1-26.3) associated with longer time to final extubation. Patients with these variants had worse outcomes than those with other de novo variants, who in turn had worse outcomes than patients with no de novo variants. Together, these data suggest that different de novo variants confer varying amounts of risk, presumably due to the gene functions that are perturbed.

There are limitations in our study. We had surgical data for about half of the cohort that had undergone genetic sequencing. However, to our knowledge, this is the first study to associate de novo CNVs with CHD phenotypes and outcomes. Our findings suggest that genetic testing of patients with CHD may provide valuable information for risk stratification and treatment planning.
the largest study that has investigated the relationship between de novo genotype and postoperative outcomes in CHD.

The absence of surgical data resulted largely because participating centers in our study began standardized surgical data collection at different times between 1991 and 2015, sometimes after patients had undergone open-heart surgery. Consistent with this, the mean age of patients with surgical data was 1.1 years, whereas that of patients without surgical data was 8.5 years, creating some differences between the groups. Patients without surgical data had fewer ECAs and were more likely to have been enrolled in this study, years after cardiac surgery. However, de novo variants occurred with comparable prevalence among patients with and without surgical data, suggesting that our inability to capture surgical cases for administrative reasons was unlikely to have biased our findings. Some patients with CHD might have had unrecognized subclinical ECAs, as phenotypes were only identified as part of clinical care, and misclassification of such subjects as ECA-negative could have contributed risk that we ascribed to genotype. Whereas all study patients received care in tertiary clinical centers from physicians with considerable expertise in recognizing syndromic CHD, future re-evaluation of these patients may improve phenotyping. Finally, our analyses examined exome sequences, which enabled broad

Figure 4. Identification and validation of high-risk de novo damaging variants.
Permuation analyses identified de novo copy number variants at 15q25.2 and 15q11.2 as high-risk for transplant-free survival (A) and 15q25.2, 22q11.21, and 3p25.1-26.3 as high-risk for prolonged time to final extubation (B). C, Kaplan-Meier curves depicting time to death or heart transplantation after first open-heart surgery in congenital heart disease (CHD) patients with high-risk de novo damaging variants (15q25.2 and 15q11.2), any other de novo damaging variants, and no de novo variants. D, Kaplan-Meier curves depicting time to final extubation after open-heart surgery in patients with high-risk de novo damaging variants (15q25.2, 22q11.21, and 3p25.1-26.3), other de novo damaging variants and no de novo variants. Adjusted hazard ratios (HR) are shown.
Detection of DGVs and CNVs spanning ≥3 exons, but excluded most intronic de novo variants and would not capture epigenetic modifiers.

We conclude that, in addition to providing insights into CHD causes, de novo genetic variants are associated with noncardiac phenotypes and negative outcomes after cardiac surgery. CHD patients with de novo variants have more ECA, require longer postoperative ventilator support and have decreased transplant-free survival. With the increased availability and reduced costs of genomic sequencing, clinical application of this technology may be warranted to identify high-risk patients with CHD before cardiac surgical interventions.

**REFERENCES**

1. Chakrabarti S, Taylor AM, Wedge DC, Wang B, et al. De novo CNV deletions and duplications in a cohort of patients with congenital heart defects. **Nat Genet.** 2011;43:1156–1162.

2. van der Loo K, Young BD, Lander ES, et al. De novo copy number variants in adults with tetralogy of Fallot implicate novel risk gene pathways. **Am J Hum Genet.** 2012;90:130–138.

3. Ayyash NM, Lattke K, Johnson S, et al. De novo CNVs in congenital heart disease with neurodevelopmental and other congenital anomalies. **Adv Genet.** 2014;84:1–39.

4. Campagnari F, Gattazzo C, Marchetti G, et al. De novo copy number variants detectable by array CGH in congenital heart disease. **Circ Genom Precis Med.** 2015;8:682–691.

5. Chakrabarti S, Taylor AM, Wedge DC, Wang B, et al. De novo CNV deletions and duplications in a cohort of patients with congenital heart defects. **Nat Genet.** 2011;43:1156–1162.

6. van der Loo K, Young BD, Lander ES, et al. De novo copy number variants in adults with tetralogy of Fallot implicate novel risk gene pathways. **Am J Hum Genet.** 2012;90:130–138.

7. Ayyash NM, Lattke K, Johnson S, et al. De novo CNVs in congenital heart disease with neurodevelopmental and other congenital anomalies. **Adv Genet.** 2014;84:1–39.

8. Campagnari F, Gattazzo C, Marchetti G, et al. De novo copy number variants detectable by array CGH in congenital heart disease. **Circ Genom Precis Med.** 2015;8:682–691.
15. Glessner JT, Bick AG, Ito K, Homsy J, Rodriguez-Murillo L, Fromer M, Mazaika E, Vardarajan B, Italia M, Leipzig J, et al. Increased frequency of de novo copy number variants in congenital heart disease by integrative analysis of single nucleotide polymorphism array and exome sequence data. Circ Res. 2014;115:884–896. doi: 10.1161/CIRCRESAHA.115.304458

16. Richards AA, Santos LJ, Nichols HA, Crider BP, Elder FF, Hauser NS, Zinn AR, Garg V. Cryptic chromosomal abnormalities identified in children with congenital heart disease. Pediatr Res. 2008;64:358–363. doi: 10.1203/PDR.0b013e31818095d0

17. Fahed AC, Gelb BD, Seidman JG, Seidman CE. Genetics of congenital heart disease: the glass half empty. Circ Res. 2013;112:707–720. doi: 10.1161/CIRCRESAHA.112.300863

18. Jin SC, Homsy J, Zaide S, Lu Q, Morton S, DePalma SR, Zeng X, Gi H, Chiang W, Sierant MC, et al. Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. Nat Genet. 2017;49:1593–1601. doi: 10.1038/ng.3970

19. Sifrim A, Hitz MP, Wilsdon A, Breckpot J, Turki SH, Thienpont B, McRae J, Fitzgerald TW, Singh T, Swaminathan GJ, et al; INTERVAL Study; UK10K Consortium; Deciphering Developmental Disorders Study. Distinct genetic architectures for syndromic and nonsyndromic congenital heart defects identified by exome sequencing. Nat Genet. 2016;48:1060–1065. doi: 10.1038/ng.3627

20. Carey AS, Liang L, Edwards J, Brandt T, Mei H, Sharp AJ, Hsu DT, Newburger JW, Ohye RG, Chung WK, et al. Effect of copy number variants on outcomes for infants with single ventricle heart defects. Circ Cardiovasc Genet. 2013;6:444–451. doi: 10.1161/CIRCGENETICS.113.00189

21. Kim DS, Kim JH, Burt AA, Crosslin DR, Burnham N, Kim CE, McDonald-McGinn DM, Zackai EH, Nicolson SC, Spray TL, et al. Burden of potentially pathologic copy number variants is higher in children with isolated congenital heart disease and significantly impairs covariate-adjusted transplant-free survival. J Thorac Cardiovasc Surg. 2016;151:1147.e4–1151.e4. doi: 10.1016/j.jtcvs.2015.09.136

22. Mercer-Rosa L, Pinto N, Yang W, Tanel R, Goldmuntz E. 22q11.2 Deletion syndrome is associated with perioperative outcome in tetralogy of Fallot. J Thorac Cardiovasc Surg. 2013;146:868–873. doi: 10.1016/j.jtcvs.2012.12.028

23. O’Byrne ML, Yang W, Mercer-Rosa L, Parnell AS, Oster ME, Levenbrown Y, Tanel RE, Goldmuntz E. 22q11.2 Deletion syndrome is associated with increased perioperative events and more complicated postoperative course in infants undergoing infant operative correction of truncus arteriosus communis or interrupted aortic arch. J Thorac Cardiovasc Surg. 2014;148:1597–1605. doi: 10.1016/j.jtcvs.2014.02.011

24. Yoshizato T, Dumitriu B, Hosokawa K, Makishima H, Yoshida K, Townsley D, Sato-Otsubo A, Sato Y, Liu D, Suzuki H, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med. 2015;373:35–47. doi: 10.1056/NEJMoa1414799

25. Ishwaran H, Kogalur UB, Blackstone EH, Lauer MS. Random survival forests. Ann Appl Stat 2008;2:841-860.

26. Simon N, Friedman J, Hastie T, Tibshirani R. Regularization paths for cox’s proportional hazards model via coordinate descent. J Stat Softw. 2011;39:1–13. doi: 10.18637/jss.v039.i05

27. Videbæk J, Laursen HB, Olsen M, Høfsten DE, Johnsen SP. Long-term nationwide follow-up study of simple congenital heart disease diagnosed in otherwise healthy children. Circulation. 2016;133:474–483. doi: 10.1161/CIRCULATIONAHA.115.017226

28. Mercer-Rosa L, Paridon SM, Fogel MA, Rychik J, Tanel RE, Zhao H, Zhang X, Yang W, Shiitst J, Goldmuntz E. 22q11.2 deletion status and disease burden in children and adolescents with tetralogy of Fallot. Circ Cardiovasc Genet. 2015;8:74–81. doi: 10.1161/CIRCGENETICS.114.000819